银屑病“克星”Wynzora乳膏治愈率高达33.7%！疗效十分可观！

Psoriasis is one of the most common skin diseases, affecting approximately 100 million people worldwide. However, Wynzora cream has made a breakthrough with its good curative effect. So what is the specific curative effect? In this article, the editor will take you to find out!

plaque psoriasis

Psoriasis is commonly known as "psoriasis". Plaque psoriasis is a chronic skin disease with a long course and easy recurrence. Some patients almost never recover throughout their lives. Most of the people affected by the disease are young adults. The typical clinical symptoms are erythema and scales. It can occur all over the body, and is more common on the scalp and extended sides of the limbs. Due to its repeated attacks, it has a greater impact on the patient's physical health and mental status. The exact cause of psoriasis is unknown and there is no cure, but symptoms can usually be well controlled with treatment.

Pictures from Google, infringement will be deleted

Wynzora Cream

In July 2020, MC2 Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Wynzora Cream (calcipotriol and betamethasone dipropionate, 0.005%/0064%) as a once-daily topical treatment for the treatment of adults with plaque psoriasis.

Wynzora Cream combines the pharmacological effects of calcipotriol as a synthetic vitamin D3 mimetic and betamethasone dipropionate as a synthetic corticosteroid.

Wynzora Cream Benefits

In April 2021, "J Drugs Dermatol" published a phase III, multi-center, randomized controlled trial to evaluate the efficacy of Wynzora cream. The primary efficacy endpoint was the proportion of patients with successful treatment at week 8. Treatment success was defined as an improvement of at least 2 levels from baseline on the Physician Global Assessment (PGA) scale, equal to "clear" or "almost clear."

A total of 794 patients were included in the trial, who were randomly assigned into three groups and were given Wynzora cream and excipient respectively, with concentrations of 0.005%/0.064%. Among them, the proportion of Wynzora cream group reaching the primary efficacy endpoint was 37.4%, while the proportion of excipient group was 3.7%. The gap between the two was 33.7%. The detailed data is shown in Figure 1:

Figure 1: Difference between the two groups in achieving the primary efficacy endpoint

To sum up, the proportion of the Wynzora cream group that achieved the primary efficacy endpoint was 37.4%, while the proportion of the excipient group was 3.7%. The gap between the two was as high as 33.7%, and the efficacy was significant!

Global research and development of psoriasis drugs

Currently, there are 978 drugs for psoriasis, in addition to Apremilast, which is already on the market. There are 389 drugs currently in the non-development stage, 101 drugs in the preclinical stage, 13 drugs in the drug discovery stage, 9 drugs in the clinical application stage, 6 drugs in unknown clinical stages, and in early clinical phase 1. There are 6 drugs in clinical stage, 91 drugs in clinical phase 1, 8 drugs in clinical phase 1/2, 130 drugs in clinical phase 2, and 52 drugs in clinical phase 3. I believe they will meet us in the near future. In addition, there are 160 drugs that have appeared in front of you. Today I will briefly introduce two kinds for you:

Deuterated colexitinib

Deuterated colexitinib was approved in the United States in September 2022 for the treatment of moderate to severe plaque psoriasis. It is the first oral therapy approved to treat this indication in the past decade and the only approved TYK2 (allosteric tyrosine kinase 2) inhibitor in the world.

Deuterated colexitinib is an allosteric tyrosine kinase 2 inhibitor developed by Bristol-Myers Squibb. It acts on the pseudokinase domain of allosteric tyrosine kinase 2 to regulate the inflammatory response. In addition to being suitable for patients with psoriasis, it can also be used to treat various autoimmune diseases such as systemic lupus erythematosus and ulcerative colitis.

Abxitinib

In April 2022, the State Food and Drug Administration approved the listing of abxitinib tablets, a Class 1 innovative drug applied by Pfizer, through the priority review and approval process.

Abxitinib is a JAK 1 (non-receptor tyrosine protein kinase 1) inhibitor. Non-receptor tyrosine protein kinase is an intracellular enzyme. By inhibiting non-receptor tyrosine protein kinase 1, this drug affects the interaction of cytokines or growth factor receptors on the cell membrane, affects cell hematopoietic function and immune cell function, thereby reducing chronic inflammation and plaque formation in the immune system, and plays a role in the treatment of psoriasis.

"Wynzora Cream is a novel topical treatment for plaque psoriasis that provides a unique combination of high efficacy, safety and excellent treatment convenience in a single product," said Dr. Linda Stein Gold, director of clinical research in dermatology at Henry Ford Health System in Detroit, Michigan.

Dr. Linda Stein Gold, picture from Google, deleted if infringement

References

[1]Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream. J Drugs Dermatol. 2021 Apr 1;20(4):420-425. doi: 10.36849/JDD.2021.5653. PMID: 33852251.

[2]Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application.Praestegaard M, Steele F, Crutchley N.Dermatol Ther (Heidelb).

[3]The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects. Marek-Jozefowicz L, Czajkowski R, Borkowska A, Nedoszytko B, Żmijewski MA, Cubała WJ, Slominski AT.